PT UBC Medical Indonesia Tbk (LABS) Fair Value & Analysis
Healthcare · ID · Market cap 525B IDR
Fair value as of: Jun 24, 2026
From 23 valuation models · updated 5 days ago
Share price +1.5% over the past month.
Price vs Fair Value (12 months)
12‑month range 124.32 IDR – 223.77 IDR · fair‑value band 61.03 IDR – 110.03 IDR · the 144.00 IDR price screens above the 89.42 IDR fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
PT UBC Medical Indonesia Tbk (LABS) currently trades at 144.00 IDR, while our model-based Fair Value estimate is 89.42 IDR — implying the stock looks roughly 37.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, PT UBC Medical Indonesia Tbk generated revenue of 206B IDR at a net margin of 5.9%. Revenue grew 19.6% year over year. It earns a return on equity of 8.2%. The balance sheet holds a net cash position of 13.7B IDR. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
PT UBC Medical Indonesia Tbk engages in the marketing and distribution of medical devices in Indonesia. The company operates in two segments, Medical Disposables and Consumables, and Diagnostics and Equipment. It offers TB management, newborn screening, HPV DNA test, real time PCR, infectious disease, extraction kit, all-in-one GP workstation, hisky, and AIRDOC products. The company also wholesale of laboratory equipment, pharmaceutical equipment, and medical equipment for human beings and animals; and chemical products and traditional medicine. The company was founded in 2014 and is based in Jakarta Timur, Jakarta. PT UBC Medical Indonesia Tbk operates as a subsidiary of PT Optel Investama Mulia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PT UBC Medical Indonesia Tbk reported revenue of 199B IDR in FY2025 versus 130B IDR in FY2021, a compound +11.3%/yr. Reported net income was 13.5B IDR in FY2025, compounding +157.3%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 1,231 MXN | -23% |
| Stryker Corporation S1YK34 | R$79.18 | R$43.78 | -45% |
| Medtronic plc MDT | $79.27 | $73.33 | -7% |
| Boston Scientific Corporation B1SX34 | R$247.01 | R$234.82 | -5% |
| Edwards Lifesciences Corporation EW | $87.45 | $41.02 | -53% |
| Siemens Healthineers AG SEMHF | $40.29 | $47.96 | +19% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PT UBC Medical Indonesia Tbk (LABS) undervalued?
What is the fair value of LABS?
What is the quality score of LABS?
What is the revenue of PT UBC Medical Indonesia Tbk (LABS)?
What is the net profit margin of LABS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.